Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accounts Payables: 2019-2025

Historic Accounts Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $2.9 million.

  • Fulcrum Therapeutics' Accounts Payables fell 29.32% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 29.32%. This contributed to the annual value of $1.2 million for FY2024, which is 57.78% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Accounts Payables is $2.9 million, which was up 63.11% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Accounts Payables registered a high of $6.0 million during Q1 2022, and its lowest value of $1.2 million during Q4 2024.
  • Its 3-year average for Accounts Payables is $3.0 million, with a median of $3.6 million in 2023.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 31.01% in 2023, then plummeted by 60.93% in 2025.
  • Fulcrum Therapeutics' Accounts Payables (Quarterly) stood at $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then fell by 24.22% to $2.8 million in 2023, then slumped by 57.78% to $1.2 million in 2024, then fell by 29.32% to $2.9 million in 2025.
  • Its Accounts Payables stands at $2.9 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.5 million for Q1 2025.